Company intelligence / Profile preview

Confluence Pharmaceuticals

Carmel, Indiana, United Statesconfluencepharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Confluence Pharmaceuticals is currently conducting Phase II clinical trials for its lead compound acamprosate for the treatment of Fragile X Syndrome. A double-blind placebo-controlled study demonstrated improvements across several disorder-relevant domains including expressive language, social engagement, anxiety, and hyperactivity.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ACP SR Sprinkles

Unknown

Partnerships

Indiana University School of MedicineCincinnati Children's Hospital Medical Center

Beyond the preview

Go deeper on Confluence Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Confluence Pharmaceuticals.

Explore the full profile